RxDoctor Payments Data

Niki Ninopoulos, PA

Medical · Albuquerque, NMNPI 1134604978

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 345 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 24.4% of the total. Among medical clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,619in general payments, 2019–2025

Across 345 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sanofi$1K
  • Johnson & Johnson$715
  • Sun Pharmaceutical Industries Inc.$466
  • Incyte Corporation$450
  • Novartis$402
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$6,29895%
  • Education$3215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,619 in reported general payments places this provider in the 95th percentile of 156 medical providers in New Mexico.

See all medical providers in New Mexico

Medicare billing

Part B allowed, 2024
$184,886
Medicare patients
668
Services billed
4,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab28$113,830
RinvoqUpadacitinib12$75,936
Betamethasone Dipropionate159$6,145
Metronidazole61$2,325
Fluocinonide69$2,264
Triamcinolone Acetonide177$2,135
Calcipotriene13$2,045
Clobetasol Propionate81$1,926
Econazole Nitrate77$1,611
Doxycycline Hyclate65$1,528
Ketoconazole85$1,325
Clindamycin Phosphate32$1,310
Minoxidil100$1,252
Fluorouracil16$953
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc53$821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,613$75,93612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 medical providers in New Mexico.

Other medical in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →